Why aTyr Pharma Stock Is Sliding Before a Key June FDA Filing
aTyr Pharma shares fell 7.9% to 47.25 cents Friday, underperforming biotech indexes, as investors awaited a planned June regulatory filing for a new Phase 3 lung-disease trial. FMR LLC disclosed a 6.1% stake in aTyr in a Schedule 13G/A. The company’s previous Phase 3 trial missed its primary endpoint. Broader markets also declined after strong U.S. jobs data.